Cross-Sector entity
Of the tracked stories, 4 of 4 also mention Antengene Corporation Limited, the most common co-covered peer. Across a 173-day span, the pace is roughly 0.2 stories per week. The busiest single day carried 2. market-trends accounts for 2 of the 4 tracked stories, while 1 other category carries the remainder.
4 verified stories tracked
Last mentioned: 1d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 4 of 4 also mention Antengene Corporation Limited, the most common co-covered peer. Across a 173-day span, the pace is roughly 0.2 stories per week. The busiest single day carried 2. market-trends accounts for 2 of the 4 tracked stories, while 1 other category carries the remainder. Each carries 2 original sources on average. AnTenGager appears in 4 tracked Cross-Sector stories published from March 4, 2026 through August 23, 2026.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AnTenGager. Shared-story counts are live from our verified record — not editorial picks.
Press Release Distribution
Company issues PRNewswire release summarizing the summit highlights.
Evercore Summit Presentation
Antengene presents R&D updates including ATG-022 clinical data, TriGager TCE platform, multiple functional modules, and ATG-207 during a fireside chat.
Clinical Filings Target
Antengene plans to submit CTAs for ATG-201 in China and Australia by the end of Q1 2026.
Investor Briefings
Antengene hosts conference calls in Chinese and English to discuss the UCB partnership.
Global License Agreement
Antengene and UCB announce exclusive worldwide licensing deal for ATG-201.
Regulatory Filings
Planned submission of clinical trial applications for ATG-201 in China and Australia.
For healthcare executives and clinical leaders, Antengene's R&D showcase highlights emerging targeted oncology and autoimmune candidates. The presentation included updated ATG-022 data and a first-in-class bifunctional fusion protein, signaling pipeline expansion that could eventually affect treatment options. Clinical teams should note the data remain limited and are not yet peer-reviewed.
For biotech and pharma professionals, Antengene's showcase demonstrates platform depth in T-cell engager engineering, adding TriGager to its AnTenGager toolbox and introducing a first-in-class αCD3-TGF-β fusion protein. The presentation also included updated ATG-022 data, though no quantitative results were disclosed. This positions Antengene as a company to watch in the crowded CLDN18.2 and TCE arenas.
Source: prnewswire.com · manilatimes.net
Antengene has granted UCB exclusive global rights to ATG-201, a CD19/CD3 bispecific T-cell engager, in a deal worth up to $1.18 billion. The partnership leverages Antengene's AnTenGager platform to target B-cell-driven autoimmune diseases, marking a major strategic expansion for both firms.
UCB has secured exclusive global rights to Antengene's ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases. The agreement includes $80 million in upfront payments and potential milestones exceeding $1.1 billion, validating Antengene's AnTenGager platform.
Source: admin (in) · admin (in)
